MWNA
RVNC

Marshall Wace North America’s Revance Therapeutics, Inc. RVNC Stock Holding History

Marshall Wace North America’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-49,645
Closed -$1.53M – 1755
2018
Q1 		$1.53M Buy
49,645
+26,385
+113% +$849K 0.01% 883
2017
Q4 		$832K Buy
+23,260
New +$668K ﹤0.01% 1032

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Marshall Wace North America's RVNC Position: Q2 2018 in Review

Marshall Wace North America sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2018, closing a stake of 49,645 shares — an estimated $1.53M sold.

Marshall Wace North America first reported a position in RVNC in Q4 2017 and held it in 2 quarters. The position peaked at $1.53M in Q1 2018. 110 funds tracked by Wall St. Rank hold RVNC as of Q2 2018.

  • Marshall Wace North America reported no remaining Revance Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Marshall Wace North America sold 49,645 Revance Therapeutics, Inc. shares in Q2 2018, an estimated $1.53M.
  • Marshall Wace North America first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 2 quarters.
  • Marshall Wace North America's Revance Therapeutics, Inc. position peaked at $1.53M in Q1 2018.
  • 110 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2018.

Based on Marshall Wace North America's 13F filing for Q2 2018, filed 14 Aug 2018.